MDB vs SRAD vs XTLB Stock Comparison

MongoDB, Sportradar Group AG and Xtl Biopharmaceuticals Prices as of Oct 27, 2026 Peers: Industry group
MDB MongoDB, Inc.
$389.84 -5.0% 1M +14.6% 1Y
Market cap
$31.70B
P/E
538.3x
Revenue (TTM)
$2.78B
Div. yield
–
Data Infrastructure Technology
7 wins
SRAD Sportradar Group AG
$12.23 -7.6% 1M -54.9% 1Y
Market cap
$12.78B
P/E
640.6x
Revenue (TTM)
$1.62B
Div. yield
–
Data Infrastructure Technology
2 wins

Head to Head

9 decided of 12

MongoDB leads on 7 of the 12 questions below (MongoDB 7, Sportradar Group AG 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMDBSRADXTLBLeader
Larger companyMarket capitalisation $31.70B $12.78B $16.49M MDB
Cheaper on earningsLower P/E, profitable companies only 538.3x 640.6x -2.3x MDB
Cheaper on forward earningsLower price / next fiscal year consensus EPS 55.7x 47.0x — SRAD
Faster revenue growthRevenue growth, trailing twelve months +25.5% +24.7% — MDB
More profitableNet margin, trailing twelve months 2.1% 1.2% — MDB
Better return on capitalReturn on invested capital — -8.6% — –
Less leveragedLower net debt / EBITDA — 1.4x — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +14.6% -54.9% -62.3% MDB
Better 5-year returnAnnualised price return, 5 years -5.0%/yr -9.5%/yr -34.7%/yr MDB
Less volatileAnnualised volatility, 1 year 72.7% 56.5% 108.7% SRAD
Higher overall scoreMean of the five percentile scores vs peers 73/100 60/100 — MDB

Percentile Scorecard

MDBSRADXTLB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMDBSRADXTLB
Valuation 46 #68 of 124 79 #27 of 124 24 #476 of 625
Growth 98 #3 of 113 63 #43 of 113 –
Profitability 71 #32 of 109 70 #33 of 109 –
Financial Health 80 #26 of 127 56 #57 of 127 2 #642 of 656
Shareholder Returns 69 #21 of 65 31 #45 of 65 –
Overall 73 60 –
  • MDB ranked among 137 companies in Infrastructure Software
  • SRAD ranked among 137 companies in Infrastructure Software
  • XTLB ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMDBSRADXTLBSPY
1 month -5.0%-7.6%-19.6% -0.2%
3 months +25.5%-17.5%-39.1% +3.9%
6 months +51.0%-1.0%-21.3% +8.2%
Year to date -7.1%-48.5%-22.0% +12.9%
1 year +14.6%-54.9%-62.3% +12.3%
3 years +16.3%+39.8%-44.8% +87.4%
3 years, per year +5.2%+11.8%-18.0% +23.3%
5 years -22.7%-39.2%-88.1% +67.9%
5 years, per year -5.0%-9.5%-34.7% +10.9%
10 years ——-89.6% +261.1%
10 years, per year ——-20.3% +13.7%

Risk

MeasureMDBSRADXTLBSPY
Volatility, 1Y 72.7%56.5%108.7% 12.7%
Downside volatility, 1Y 76.7%64.3%90.3% 12.7%
Beta vs S&P 500, 1Y 1.900.560.54 1.00
Return / volatility, 1Y 0.20-0.97-0.57 0.97
Max drawdown, 5Y -76.5%-69.0%-88.9% -25.4%
From 52-week high -17.5%-54.9%-62.3% -1.2%
52-week high $472.29$27.11$4.80 $779.14
52-week low $225.95$11.56$1.78 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMDBSRADXTLB
P/E now vs peer median 532.8xmedian 38.6x 635.9xmedian 38.6x -2.3xmedian 17.2x
P/S now vs peer median 11.3xmedian 4.4x 2.4xmedian 4.4x 2,447xmedian 9.0x
EV/EBITDA now vs peer median 2,347xmedian 34.5x -13.9xmedian 34.5x —median 16.3x
P/FCF now vs peer median 47.7xmedian 29.4x 7.5xmedian 29.4x -16.7xmedian 18.7x
P/B now vs peer median 10.5xmedian 3.3x 4.3xmedian 3.3x -67.4xmedian 2.2x
PEG now vs peer median 17.67median 1.28 21.97median 1.28 —median 0.33

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMDBSRADXTLB
Revenue $2.78B $1.62B –
Gross profit $2.02B – –
Operating income -$14.52M – –
Net income $58.90M $19.94M –
Free cash flow $659.02M $510.26M –
R&D $780.02M $44.37M –
EPS (diluted) $0.72 $64,328.88 –
Cash & equivalents $1.00B $286.82M $76.00K
Total debt – $49.28M $530.00K
Shares (diluted) 82.00M 310.00 8.96M
Enterprise value $22.17B $11.06B $13.29M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMDBSRADXTLB
P/E 532.8x 635.9x -2.3x
P/FCF 47.7x 7.5x -16.7x
P/Operating cash flow 47.1x 7.6x –
P/S 11.3x 2.4x 2,447x
P/B 10.5x 4.3x -67.4x
P/Tangible book 10.6x 4.3x -67.4x
EV/EBITDA 2,347x -13.9x –
EV/EBIT -1,996x -41.3x –
EV/Revenue 10.4x 2.1x –
EV/FCF 44.0x 6.8x –
EV/Operating cash flow 43.5x 6.9x –
PEG (3Y EPS CAGR) 17.67 21.97 –

Growth

14 metrics
MetricMDBSRADXTLB
Revenue growth (1Y) 25.5% 24.7% –
Revenue CAGR (3Y) 23.2% 23.9% –
Gross profit growth (1Y) 26.1% – –
Gross profit CAGR (3Y) 22.5% – –
Operating income growth (1Y) 91.2% – –
Operating income CAGR (3Y) 62.4% – –
Net income growth (1Y) 174.9% -83.5% –
Net income CAGR (3Y) 30.9% 51.8% –
EPS growth (1Y) 174.1% -94.7% –
EPS CAGR (3Y) 30.1% 28.9% –
Operating cash flow growth (1Y) 146.9% 15.0% –
Operating cash flow CAGR (3Y) 139.5% 30.5% –
Free cash flow growth (1Y) 174.7% 15.7% –
Free cash flow CAGR (3Y) 144.3% 30.7% –

Profitability

14 metrics
MetricMDBSRADXTLB
Gross margin 72.7% – –
EBITDA margin 0.4% -15.4% –
Operating margin -0.5% – –
Pretax margin 2.7% 1.4% –
Net margin 2.1% 1.2% –
FCF margin 23.7% 31.6% –
Operating cash flow margin 24.0% 31.0% –
Return on equity 2.0% 2.1% –
Return on assets 1.6% 0.7% –
Return on invested capital – -8.6% –
Return on capital employed -0.5% -3.5% –
Asset turnover 0.7x 0.5x –
Cash conversion (OCF / net income) 11.3x 25.1x –
Stock comp / revenue 20.3% 4.2% –

Financial Health

11 metrics
MetricMDBSRADXTLB
Debt / assets – 0.4% 83.1%
Debt / equity – 0.0x -0.5x
Net debt / EBITDA – 1.4x –
Debt / FCF – 0.0x –
Liabilities / assets 21.1% 69.5% 253.0%
Equity / assets 78.9% 30.5% -153.0%
Interest coverage -6.1x -0.8x –
Current ratio 4.9x 1.0x 0.4x
Quick ratio 4.5x 0.9x 0.4x
Cash ratio 3.8x 0.6x 0.2x
Altman Z-score 24.44 1.75 –

Shareholder Returns

7 metrics
MetricMDBSRADXTLB
Dividend yield – – –
Net buyback yield 1.2% -1.0% –
Shareholder yield 1.2% -1.0% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMDBSRADXTLB
Forward P/E 55.7xFY2026 47.0xFY2026 –
EPS, next fiscal year $7.00FY2026 $0.26FY2026 –
EPS growth, next FY +40.8%FY2026 -27.8%FY2026 –
EPS growth, the year after +6.4% +100.0% –
Revenue, next fiscal year $2.89BFY2026 $1.65BFY2026 –
Revenue growth, next FY +17.5%FY2026 +8.4%FY2026 –
Revenue growth, the year after +33.4% +10.8% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMDBSRADXTLB
Held by institutions 92.6% 17.8% –
Institutions holding 870 151 –
Change in shares held, QoQ +4.3% -2.8% –
Institutions buying 493 88 –
Institutions selling 278 42 –
Buyers to sellers 1.77 2.10 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MDBSRADXTLB
MDB 1.00 0.24 -0.10
SRAD 0.24 1.00 0.03
XTLB -0.10 0.03 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MDB, SRAD and XTLB?

MongoDB (MDB) is the largest by market capitalisation: MongoDB (MDB) $31.70B, Sportradar Group AG (SRAD) $12.78B, Xtl Biopharmaceuticals (XTLB) $16.49M.

Which stock is cheaper, MDB, SRAD and XTLB?

MongoDB (MDB) trades on the lowest price-to-earnings ratio (MongoDB (MDB) 538.3x, Sportradar Group AG (SRAD) 640.6x, Xtl Biopharmaceuticals (XTLB) -2.3x). On next year's consensus earnings, Sportradar Group AG (SRAD) is cheapest (MongoDB (MDB) 55.7x, Sportradar Group AG (SRAD) 47.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

MongoDB (MDB) grew revenue fastest over the trailing twelve months: MongoDB (MDB) +25.5%, Sportradar Group AG (SRAD) +24.7%.

Which company is more profitable?

MongoDB (MDB) has the highest net margin (MongoDB (MDB) 2.1%, Sportradar Group AG (SRAD) 1.2%).

Which stock has performed better?

Over the past year MongoDB (MDB) returned the most: MongoDB (MDB) +14.6%, Sportradar Group AG (SRAD) -54.9%, Xtl Biopharmaceuticals (XTLB) -62.3%. Over five years, MongoDB (MDB) compounded fastest (MongoDB (MDB) -5.0%/yr, Sportradar Group AG (SRAD) -9.5%/yr, Xtl Biopharmaceuticals (XTLB) -34.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Sportradar Group AG (SRAD) has been the steadiest (MongoDB (MDB) 72.7%, Sportradar Group AG (SRAD) 56.5%, Xtl Biopharmaceuticals (XTLB) 108.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, MDB, SRAD and XTLB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, MongoDB (MDB) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.